lncRNA MIAT、LASP1蛋白在甲状腺癌组织中的表达及预后相关性分析

Expressions of lncRNA MIAT and LASP1 proteins in thyroid cancer and their correlations with prognosis

目的研究长链非编码RNA心肌梗死相关转录本(lncRNA MIAT)、LIM和SH3蛋白1(LASP1)蛋白在甲状腺癌组织中的表达及二者与预后的关系。方法选取2014年6月—2016年12月103例甲状腺癌患者作为研究对象,检测患者甲状腺癌组织和癌旁组织中lncRNA MIAT和LASP1表达情况,分析lncRNA MIAT、LASP1表达水平与甲状腺癌患者临床病理特征及患者预后的关系。结果与癌旁组相比,甲状腺癌组lncRNA MIAT表达水平、LASP1阳性表达率较高(P<0.05)。lncRNA MIAT、LASP1在甲状腺癌组织中的表达水平与患者UICC分期、淋巴结转移相关(P<0.05)。lncRNA MIAT高表达组和LASP1阳性组复发率、淋巴结转移率分别高于lncRNA MIAT低表达组和LASP1阴性组(P<0.05)。淋巴结有转移、lncRNA MIAT高表达、LASP1阳性是影响甲状腺癌患者预后不良的独立危险因素(P<0.05)。结论甲状腺癌组织lncRNA MIAT表达水平上调,LASP1阳性表达率较高,可能成为评价甲状腺癌预后的临床指标。

Objective To study the expressions of long non-coding RNA myocardial infarction association transcript(lncRNA MIAT),LIM and SH3 protein 1(LASP1)in thyroid cancer tissues and their relationships with prognosis.Methods A total of 103 patients with thyroid cancer from June 2014 to December 2016 were selected as the study subjects,and the expressions of lncRNA MIAT,LASP1 in thyroid cancer and precancerous tissues were detected.The relationships between the expression levels of lncRNA MIAT,LASP1 and the clinicopathological characteristics of patients with primary thyroid cancer,and the prognosis of patients were analyzed.Results Compared with the paracancerous group,the levels of lncRNA MIAT and the positive expression rate of LASP1 in thyroid cancer group was higher(P<0.05).The levels of lncRNA MIAT and LASP1 in thyroid cancer were correlated with UICC stage and lymph node metastasis(P<0.05).The recurrence rate and lymph node metastasis rate of lncRNA MIAT high expression group and LASP1 positive group were higher than those of lncRNA MIAT low expression group and LASP1 negative group,respectively(P<0.05).Lymph node metastasis,high expressions of lncRNA MIAT and positive LASP1 were independent risk factors for poor prognosis in patients with thyroid cancer(P<0.05).Conclusion The expression of lncRNA MIAT was up-regulated in thyroid carcinoma,and the positive rate of LASP1 was higher,and may be clinical indexes to evaluate the prognosis of patients with thyroid cancer.